Treatment of Intraocular Hemorrhage
For intraocular hemorrhage, immediate management depends on the location and cause: anti-VEGF agents (ranibizumab, aflibercept, or bevacizumab) are first-line for hemorrhage associated with retinal vein occlusions and macular edema, while surgical intervention with vitrectomy is indicated for massive hemorrhages that obscure vision or cause uncontrolled intraocular pressure elevation.
Management Algorithm by Hemorrhage Type and Location
Retinal Vein Occlusion-Related Hemorrhage with Macular Edema
Anti-VEGF therapy is the preferred initial treatment based on multiple level I studies 1:
- Initiate monthly intravitreal anti-VEGF injections immediately - delay in treatment is deleterious to visual outcomes 1
- FDA-approved options: ranibizumab 0.5 mg or aflibercept
- Off-label alternative: bevacizumab (shown similar efficacy to aflibercept in SCORE2 trial) 1
- Expected outcomes: 55-61% of patients gain ≥15 letters with ranibizumab; 56% with aflibercept 1
Critical pitfall: Eyes randomized to delayed treatment (after 6 months) never achieved the same visual gains as those treated immediately, emphasizing the importance of prompt initiation 1.
Pre-Injection Protocol
- Apply topical povidone-iodine before all intravitreal injections 1
- Do not use routine prophylactic antibiotic drops - not recommended 1
Massive Intraocular Hemorrhage (e.g., from central retinal artery)
When hemorrhage is severe enough to obscure fundus view or originates from arterial sources 2:
- Perform pars plana vitrectomy under general anesthesia rather than local anesthesia 2
- Rationale: General anesthesia allows better blood pressure control, facilitating hemostasis
- Intraoperative hemostasis techniques:
Submacular Hemorrhage
Treatment selection depends on hemorrhage volume and duration 4:
- Small/moderate hemorrhages: Pneumatic displacement ± tissue plasminogen activator (tPA)
- Large hemorrhages: Surgical evacuation with tPA
- Observation alone: Only for minimal hemorrhages with good visual potential
The preoperative amount of subretinal blood dictates treatment modality 4.
Intraocular Pressure Management
Acute IOP Elevation from Hemorrhage
For hyphema or hemorrhage-related IOP spikes 5, 6:
- Address the underlying cause first - eliminate bleeding source
- Pharmacologic options based on severity:
Mechanism-Specific Considerations
Intraocular hemorrhages create conditions favoring rebleeding 5:
- Blood dilution by aqueous humor forms unstable hemostatic plugs
- Iris and choroid contain high fibrinolytic activators causing premature clot dissolution
- High local fibrin degradation products have anticoagulant effects
Consider fibrinolytic inhibitors for hyphema and subretinal hemorrhages to prevent rebleeding 5.
Corticosteroid Considerations
If anti-VEGF therapy fails or shows inadequate response 1:
- Intravitreal corticosteroids or corticosteroid implants are second-line
- Monitor IOP closely - pressure elevations are particularly common with corticosteroid use 1
- Grid laser photocoagulation may be added as adjunctive therapy
Special Circumstances
Post-Surgical or Trauma-Related Hemorrhage
- Urgent ophthalmology consultation required 8
- Onset of eye pain or visual loss after thrombolytic agent administration warrants immediate evaluation for ocular/orbital hemorrhage 8
- Prompt diagnosis and treatment improve visual outcomes 8
Systemic Evaluation
Address underlying vascular risk factors 1:
- 48% of retinal vein occlusions attributable to hypertension
- 20% to hyperlipidemia
- 5% to diabetes
- Coordinate with primary care for cardiovascular risk management
Monitoring Parameters
- Long-term IOP fluctuations are independent risk factors for progression in advanced disease 9
- Disc hemorrhage presence increases progression risk additively with IOP fluctuations 9
- Patients with both factors require vigorous treatment and close monitoring
The favorable risk-benefit profile of anti-VEGF agents makes them preferred over corticosteroids or laser as initial therapy for hemorrhage-related macular edema 1.